Handbook of Neurourology Theory and Practice Second Edition
Intravesical Drug Therapy
Publication
, Chapter
Purves, JT
January 1, 2023
Intravesical drug therapy for neurogenic bladder is currently limited to oxybutynin where higher drug levels can be achieved with lower side effect profiles than via the oral route. The glycosaminoglycan layer over the urothelial barrier presents a major obstacle that prevents the efficient delivery of larger molecules into the tissue from the lumen. Current investigations are exploring the use of liposomes, nanops, and electromotive gradients to enhance drug delivery. Investigational agents such as botulinum toxin, siRNA, and chemotherapeutic immunomodulators offer the potential for expanding the intravesical drug arsenal as the means for drug delivery improve.
Duke Scholars
Citation
APA
Chicago
ICMJE
MLA
NLM
Purves, J. T. (2023). Intravesical Drug Therapy. In Handbook of Neurourology Theory and Practice Second Edition (pp. 385–388). https://doi.org/10.1007/978-981-99-1659-7_30
Purves, J. T. “Intravesical Drug Therapy.” In Handbook of Neurourology Theory and Practice Second Edition, 385–88, 2023. https://doi.org/10.1007/978-981-99-1659-7_30.
Purves JT. Intravesical Drug Therapy. In: Handbook of Neurourology Theory and Practice Second Edition. 2023. p. 385–8.
Purves, J. T. “Intravesical Drug Therapy.” Handbook of Neurourology Theory and Practice Second Edition, 2023, pp. 385–88. Scopus, doi:10.1007/978-981-99-1659-7_30.
Purves JT. Intravesical Drug Therapy. Handbook of Neurourology Theory and Practice Second Edition. 2023. p. 385–388.